Page 10 - Indian Pharma Companies
Are the markets entering a consolidation phase? Here's what charts suggest
Markets started the first trading day of August 2020 lower, with the S&B BSE Sensex slipping over 400 points in intra-day deals
 "Are the markets entering a consolidation phase? Here's what charts suggest")
Sanofi India: Sturdy balance sheet, cash-generation augur well for company
High growth visibility in chronics, strong balance sheet will help sustain premium valuation
 "Sanofi India: Sturdy balance sheet, cash-generation augur well for company")
Trailing in the value chain: Domestic pharma's unfinished agenda
In the first of a 5-part series, we look at reasons keeping Indian pharma sector from becoming the best globally
 "Trailing in the value chain: Domestic pharma's unfinished agenda")
Adar Poonawalla: A rare risk-taking CEO with strong business acumen
Adar Poonawalla's Serum Institute has tied up with AstraZeneca-backed Oxford vaccine candidate for one billion doses which it will make for India and the GAVI vaccine alliance of 58 countries
 "Adar Poonawalla: A rare risk-taking CEO with strong business acumen")
Covid-19 crisis: Briton Pharma gets DCGI nod to launch favipiravir
Pune-based Brinton Pharmaceuticals said on Thursday it had got the nod from the Drugs Controller General of India (DCGI) to market its brand Faviton, priced at Rs 59 per tablet
 "Covid-19 crisis: Briton Pharma gets DCGI nod to launch favipiravir")
Govt notifies incentive scheme for local API manufacturing to cut imports
According to a government notification, bulk drugs accounted for 63 per cent of total pharmaceutical imports in the country in 2018-19.
 "Govt notifies incentive scheme for local API manufacturing to cut imports")
We want to price Covid-19 vaccine below Rs 1,000: Serum Institute CEO
Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222
 "We want to price Covid-19 vaccine below Rs 1,000: Serum Institute CEO")
India seeks new preferential treatment from US on drugs, other goods
India accounts for 40 per cent of US generic drug imports, including the anti-malarial hydroxychloroquine, touted by US President Donald Trump in the fight against Covid-19.
 "India seeks new preferential treatment from US on drugs, other goods")
Bharat Biotech to Zydus: Seven Indian firms race to develop Covid vaccine
Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within months because of the pandemic
 "Bharat Biotech to Zydus: Seven Indian firms race to develop Covid vaccine")
Pharma SMEs will overcome short-term disruptions: CRISIL SME Tracker
Short-term disruptions include high input costs and various operational challenges.
Covid-19 crisis: Race to develop vaccine gets a booster as field widens
On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.
 "Covid-19 crisis: Race to develop vaccine gets a booster as field widens")
China crisis, India scouting for APIs a shot in arm for sick pharma PSU
Govt is trying to reduce dependence on China for APIs and develop indigenous sources
 "China crisis, India scouting for APIs a shot in arm for sick pharma PSU")
Covid-19 crisis: Bharat Biotech's vaccine gets nod for human trials
The SARS-CoV-2 strain was isolated at National Institute of Virology (Pune), an institute under the ICMR, and transferred to Bharat Biotech.
 "Covid-19 crisis: Bharat Biotech's vaccine gets nod for human trials")
India's coronavirus drug market set for price war as firms ready launches
Sources say Cipla-BDR's favipiravir will be at least 30 per cent cheaper than Glenmark's price of Rs 103 per tablet. Cipla did not confirm.
 "India's coronavirus drug market set for price war as firms ready launches")
Cadila-CSIR's sepsis drug shows promise in fight against Covid-19
The public-private partnership trial-generated data will be soon presented before the country's drug regulator to see if it can get emergency-use authorisation.
 "Cadila-CSIR's sepsis drug shows promise in fight against Covid-19")
Covid-19 crisis: Made-in-India remdesivir may come by end of June
Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.
 "Covid-19 crisis: Made-in-India remdesivir may come by end of June")
Maharashtra may procure remdesivir from Bangladesh to treat Covid patients
State government to procure 10,000 vials for Rs 12 crore
 "Maharashtra may procure remdesivir from Bangladesh to treat Covid patients")
Amidst controversy, Indian companies continue to manufacture HCQ
Once touted as a 'wonder drug', HCQ has been battling global controversies around its safety and efficacy as a prophylactic against the new coronavirus SARS-CoV-2.
 "Amidst controversy, Indian companies continue to manufacture HCQ")
30 groups in India working on coronavirus vaccine, 20 at 'good pace'
ICMR conducting study on presence of antibodies in people, results next week
 "30 groups in India working on coronavirus vaccine, 20 at 'good pace'")
India allows export of paracetamol API amid coronavirus outbreak
The Indian government in March put a hold on exports of several drugs including paracetamol to secure supplies for its people after COVID-19 outbreak disrupted the industry's supply chain globally.
